Several other equities analysts have also recently commented on BIOC. Zacks Investment Research upgraded Biocept from a hold rating to a buy rating and set a $1.25 target price for the company in a research report on Wednesday, February 13th. Maxim Group restated a buy rating and set a $3.00 target price on shares of Biocept in a research report on Thursday, May 9th.
Shares of NASDAQ BIOC opened at $1.08 on Tuesday. The firm has a market capitalization of $18.47 million, a PE ratio of -0.12 and a beta of 2.17. Biocept has a fifty-two week low of $0.66 and a fifty-two week high of $12.15. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.72 and a quick ratio of 2.63.
An institutional investor recently bought a new position in Biocept stock. Northern Trust Corp bought a new position in shares of Biocept Inc (NASDAQ:BIOC) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 21,739 shares of the medical research company’s stock, valued at approximately $25,000. Northern Trust Corp owned approximately 0.12% of Biocept as of its most recent SEC filing. 2.34% of the stock is owned by institutional investors.
Biocept Company Profile
Biocept, Inc, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms.
See Also: How Short Selling Works
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with MarketBeat.com's FREE daily email newsletter.